PACS Group Holds Zacks Rank #1 With Forward P/E 17.4 and 25.5% Upside
PACS Group holds a Zacks Rank #1 with a forward P/E of 17.43 and PEG of 1.16, outperforming Medpace’s respective 27.34 and 2.23 and earning a Value grade of B. Analysts’ consensus targets imply approximately 25.5% upside as PACS’s earnings estimates rose 0.5% over the past 60 days.
1. Strong Buy Rating and Estimate Revisions
PACS Group carries a Zacks Rank #1 and has seen its next fiscal year earnings estimates increase by 0.5% over the past 60 days, reflecting improving analyst outlook and upward revision trends.
2. Valuation Comparison with Medpace
The company’s forward P/E stands at 17.43 and PEG ratio at 1.16, compared with Medpace’s respective 27.34 and 2.23, while PACS’s P/B ratio of 5.98 versus Medpace’s 28.58 underpins its stronger valuation appeal.
3. Analyst Price Targets Signal 25.5% Upside
Consensus analyst price targets for PACS Group imply roughly a 25.5% upside, driven by positive estimate revisions and perceived undervaluation.
4. Market Valuation Versus S&P
PACS Group’s trailing P/E of 18.43 is lower than the S&P’s 22.04 benchmark, and the company holds a Value Score of A, highlighting its attractiveness for value-focused investors.